Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations

Clin Infect Dis. 2014 Oct;59(7):920-2. doi: 10.1093/cid/ciu501. Epub 2014 Aug 4.

Authors

Michael N Oxman¹, Kenneth E Schmader²

Affiliations

¹ Infectious Diseases Section, Medicine Service, Veterans Affairs San Diego Healthcare System Division of Infectious Diseases, University of California San Diego School of Medicine.
² Geriatric Research, Education and Clinical Center, Durham Veterans Affairs Medical Center Department of Medicine, Duke University, Durham, North Carolina.

PMID: 25097080
DOI: 10.1093/cid/ciu501

No abstract available

Keywords: cancer chemotherapy; herpes zoster; immunization; varicella-zoster virus; zoster vaccine.

Publication types

Editorial
Comment

MeSH terms

Antineoplastic Agents / therapeutic use*
Female
Herpes Zoster / epidemiology*
Herpes Zoster / prevention & control*
Herpes Zoster Vaccine / administration & dosage*
Herpes Zoster Vaccine / immunology*
Humans
Male
Neoplasms / complications*

Substances

Antineoplastic Agents
Herpes Zoster Vaccine

Grants and funding

P30 AG028716/AG/NIA NIH HHS/United States